Drotrecogin alfa in patients with burns and soft tissue injury

Journal of Burn Care and Research

Volumn 29, Issue 4, 2008, Pages 676-678

  Brunsvold, Melissa E ^a   Arbabi, Saman ^b   Dimo, Mary ^c   Wahl, Wendy ^d  

^a Department of Surgery ^*

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Trauma Burn Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BURN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG FATALITY; ERYTHROCYTE TRANSFUSION; FULMINATING PURPURA; HUMAN; NECROTIZING FASCIITIS; PRESCHOOL CHILD; REFRACTORY THROMBOCYTOPENIA; SCHOOL CHILD; SEPSIS; SOFT TISSUE INJURY; THERMAL INJURY; TOXIC EPIDERMAL NECROLYSIS; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION; ANAPHYLACTOID PURPURA; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BURNS; CHILD; CHILD, PRESCHOOL; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; INFUSIONS, INTRAVENOUS; INJURY SEVERITY SCORE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROTEIN C; PURPURA, SCHOENLEIN-HENOCH; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEPSIS;

EID: 56149112462     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31817db994     Document Type: Article

References (11)

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-874.
2. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
3. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-19.
4. Payen D, Sablotzki A, Barie PS, et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in large surgical cohort. Surgery 2007;141:548-561.
5. Saffle JR, Sullivan JJ, Tuohig Gm, et al. Multiple organ failure in patients with thermal injury. Crit Care Med 1993;21: 1673-1683.
6. Cumming J, Purdue GF, Hunt JL, et al. Objective estimates of the incidence and consequences of multiple organ dysfunction and sepsis after burn trauma. J Trauma 2001;50: 510-515.
7. Weintraub J, Satterwhite T, Allo M. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach. Burns 2006;32:783-787.
8. Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160-165.
9. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823.
10. Angus DC, Laterre PF, Helterbrand, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199-2206.
11. Ferreira FL, Bota P, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001;286:1754-1758.